181 related articles for article (PubMed ID: 23145032)
1. Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.
Yadav D; Paliwal S; Yadav R; Pal M; Pandey A
PLoS One; 2012; 7(11):e48942. PubMed ID: 23145032
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
3. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
5. Virtual Screening for HIV Protease Inhibitors Using a Novel Database Filtering Procedure.
Takkis K; García-Sosa AT; Sild S
Mol Inform; 2015 Jun; 34(6-7):485-92. PubMed ID: 27490392
[TBL] [Abstract][Full Text] [Related]
6. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
[TBL] [Abstract][Full Text] [Related]
8. Pocket-to-Lead: Structure-Based
Kojima E; Iimuro A; Nakajima M; Kinuta H; Asada N; Sako Y; Nakata Z; Uemura K; Arita S; Miki S; Wakasa-Morimoto C; Tachibana Y
J Med Chem; 2022 Apr; 65(8):6157-6170. PubMed ID: 35416651
[TBL] [Abstract][Full Text] [Related]
9. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors.
Gupta SP; Babu MS
Bioorg Med Chem; 1999 Nov; 7(11):2549-53. PubMed ID: 10632065
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
12. Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.
Debnath AK
J Med Chem; 2003 Oct; 46(21):4501-15. PubMed ID: 14521412
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Qiu X; Zhao GD; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
Dou Y; Zhu M; Dong B; Wang JX; Zhang GN; Zhang F; Wang YC
Bioorg Med Chem Lett; 2020 Apr; 30(7):127019. PubMed ID: 32057582
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
[TBL] [Abstract][Full Text] [Related]
16. Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3.
Kumar BV; Kotla R; Buddiga R; Roy J; Singh SS; Gundla R; Ravikumar M; Sarma JA
J Mol Model; 2011 Jan; 17(1):151-63. PubMed ID: 20393763
[TBL] [Abstract][Full Text] [Related]
17. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
[TBL] [Abstract][Full Text] [Related]
18. QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors.
Saranya N; Selvaraj S
Curr Comput Aided Drug Des; 2012 Mar; 8(1):10-49. PubMed ID: 21999608
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential HIV-1 integrase strand transfer inhibitors: in silico virtual screening and QM/MM docking studies.
Reddy KK; Singh SK; Tripathi SK; Selvaraj C
SAR QSAR Environ Res; 2013; 24(7):581-95. PubMed ID: 23521430
[TBL] [Abstract][Full Text] [Related]
20. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations.
Tzoupis H; Leonis G; Durdagi S; Mouchlis V; Mavromoustakos T; Papadopoulos MG
J Comput Aided Mol Des; 2011 Oct; 25(10):959-76. PubMed ID: 21969102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
